WENDY L YARNO
CIK 1181186 · Chief Marketing Officer · last filed 2026-06-29
WENDY L YARNO is a Chief Marketing Officer who has filed 106 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for TARS, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$11.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.76M
12
106
-$11.91M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TARS | Director | 16,654 | $58.95 | $981.8K | $0 | 12 | 2026-06-29 |
| IDYA | Director | — | $36.16 | — | $0 | 8 | 2026-06-18 |
| INO | Director | 10,512 | $1.03 | $10.8K | $0 | 16 | 2026-05-21 |
| IOVA | Director | — | $4.70 | — | $0 | 5 | 2025-06-17 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | 0 | $68.49 | $0 | $0 | 7 | 2022-10-06 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 3,708 | — | — | $50.0K | 8 | 2020-06-23 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | Director | 0 | — | — | $0 | 7 | 2019-07-18 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Director | 5,000 | — | — | $50.0K | 5 | 2019-05-28 |
| MEDIVATION, INC. (MDVN) Delisted | Director | 32,742 | — | — | $0 | 5 | 2016-06-23 |
| ST JUDE MEDICAL, LLC (STJ) Delisted | Director | 30,240 | — | — | -$1.48M | 19 | 2016-06-03 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | — | — | — | $0 | 2 | 2014-11-18 |
| MRK | Chief Marketing Officer | 36,144 | $131.82 | $4.76M | -$10.52M | 8 | 2008-03-04 |
Recent Filings
106 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-29 | TARS | Grant (A) | — | $0 | EDGAR |
| 2026-06-18 | IDYA | Grant (A) | — | $0 | EDGAR |
| 2026-06-16 | TARS | Exer (M) | +2,954 | $0 | EDGAR |
| 2026-05-21 | INO | Grant (A) | — | $0 | EDGAR |
| 2025-06-26 | IDYA | Grant (A) | — | $0 | EDGAR |
| 2025-06-17 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | TARS | Mixed | +3,350 | $0 | EDGAR |
| 2025-05-21 | INO | Exer (M) | +2,167 | $0 | EDGAR |
| 2024-06-25 | TARS | Exer (M) | +3,350 | $0 | EDGAR |
| 2024-06-14 | TARS | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.